Skip to main content

Table 3 Summary of the pregnancy outcomes for each treatment group

From: A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border

Baseline characteristic DP ASMQ AL+ p value
Malaria
 Malaria before 28 weeks EGA 97/172 (56%) 89/169 (53%) 96/170 (56%)  
 Malaria before 37 weeks EGA 165/172 (96%) 153/169 (91%) 162/170 (95%)  
Follow-up
 Followed up until ≥ 28 weeks 91/97 (94%) 85/89 (96%) 92/96 (96%)  
 Followed up until delivery 157/172 (91%) 152/169 (90%) 159/170 (94%)  
Birth outcomes
 Twins 1/157 (1%) 0/152 (0%) 2/159 (1%)  
 Miscarriage 1/91 (1%) 1/85 (1%) 1/90 (1%) 1.00
 Stillbirth 1/155 (1%) 2/151 (1%) 2/156 (1%) 0.87
 Congenital abnormality 2/155 (1%) 0/151 (0%) 3/156 (2%) 0.38
 Male 70/155 (45%) 75/151 (50%) 75/155 (48%) 0.73
 EGA (week)* 38.8 (1.9) 39.0 (2.0) 38.8 (2.1) 0.56
 Preterm birth* 13/145 (9%) 8/135 (6%) 14/143 (10%) 0.45
 Birthweight weighed within 3 days* 134/152 (88%) 130/148 (88%) 136/150 (91%)  
 Birthweight (g)* 2860 (493) 2926 (396) 2881 (524) 0.51
 Small for gestational age* 32/133 (24%) 34/129 (26%) 38/135 (28%) 0.76
 Low birthweight* 28/134 (21%) 14/130 (11%) 26/136 (19%) 0.06
 Height (cm)* 48.8 (2.7) 49.3 (2.6) 49.0 (3.3) 0.48
 Arm circumference (cm)* 10.4 (1.1) 10.5 (0.9) 10.3 (1.2) 0.47
 Head circumference (cm)* 32.0 (1.6) 32.2 (1.7) 31.9 (1.8) 0.41
 Apgar 5 min*
  0–3 0/115 (0%) 1/116 (1%) 3/125 (2%) 0.17
  4–6 1/115 (1%) 0/116 (0%) 3/125 (2%)  
  7–10 114/115 (99%) 115/116 (99%) 119/125 (95%)  
 Placental weight (g)* 508 (111) 510 (95) 510 (121) 0.98
  1. AL+ artemether-lumefantrine extended regimen, ASMQ artesunate-mefloquine, BMI body mass index, DP dihydroartemisinin-piperaquine, EGA estimated gestational age, Pf Plasmodium falciparum, Pm Plasmodium malariae, Pv Plasmodium vivax. P value by Fisher’s exact test or ANOVA test. Figures are shown in mean (standard deviation) or number (%).
  2. *Include only live singleton births without congenital abnormality
  3. Include only those who were weighted within 3 days